A comprehensive view of Eli Lilly & Co.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Eli Lilly partners with digital therapeutics firm Sidekick Health to launch integrated digital therapeutics solution in Germany to provide tailored treatment plan for breast cancer patients; other international markets for solution under consideration

Eli Lilly selling 150,000 doses of monoclonal antibody bebtelovimab co-developed with AbCellera to US government for US$275M, with delivery beginning immediately; bebtelovimab combats COVID-19, offers neutralization activity against all know variants

Eli Lilly supplying Aveo Oncology with Erbitux cetuximab for North American clinical trial evaluating Aveo’s ficlatuzumab with cetuximab to treat metastatic head, neck squamous cell carcinoma; Merck KGaA providing cetuximab outside of US, Canada

FDA approves Eli Lilly’s Olumiant oral treatment for alopecia areata, an autoimmune disorder that causes sudden hair loss; once-daily pill is first treatment of its kind and is available by prescription only

FDA approves Eli Lilly’s NDA oral Olumiant tablet containing baricitinib 1 mg, 2 mg in 2 formulations; drug is available by prescription only and has no therapeutic equivalents

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count